Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroergotamine
- Development stage
- Approved
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intranasal
01
Overview
Dihydroergotamine is an ergot alkaloid used for the acute treatment of migraine headaches (with or without aura) and cluster headaches. It acts primarily as an agonist at serotonin 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of pro-inflammatory neuropeptide release in the trigeminal system. Dihydroergotamine also binds with high affinity to other serotonin receptors (5-HT1A, 5-HT2A, 5-HT2C), noradrenaline alpha receptors (α2A, α2B), and dopamine D2L and D3 receptors. The drug is not indicated for migraine prevention or for hemiplegic/basilar migraines. Its use has largely been supplanted by triptans due to their greater selectivity and improved side effect profile[1][2][6].
- Brand names
- D.H.E. 45MigranalTrudhesa
- Other names
- dihydroergotamineDHE
02
Targets
ADRA2A (α2A)ADRA2B (α2B)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1D (5-hydroxytryptamine receptor 1D)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on dihydroergotamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroergotamine.